Cargando…

Evogliptin Suppresses Calcific Aortic Valve Disease by Attenuating Inflammation, Fibrosis, and Calcification

Calcific aortic valve disease (CAVD) accompanies inflammatory cell infiltration, fibrosis, and ultimately calcification of the valve leaflets. We previously demonstrated that dipeptidyl peptidase-4 (DPP-4) is responsible for the progression of aortic valvular calcification in CAVD animal models. As...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Bongkun, Kim, Eun-Young, Kim, Ji-Eun, Oh, Soyoon, Park, Si-On, Kim, Sang-Min, Choi, Hyuksu, Song, Jae-Kwan, Chang, Eun-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824080/
https://www.ncbi.nlm.nih.gov/pubmed/33401457
http://dx.doi.org/10.3390/cells10010057
_version_ 1783639989358166016
author Choi, Bongkun
Kim, Eun-Young
Kim, Ji-Eun
Oh, Soyoon
Park, Si-On
Kim, Sang-Min
Choi, Hyuksu
Song, Jae-Kwan
Chang, Eun-Ju
author_facet Choi, Bongkun
Kim, Eun-Young
Kim, Ji-Eun
Oh, Soyoon
Park, Si-On
Kim, Sang-Min
Choi, Hyuksu
Song, Jae-Kwan
Chang, Eun-Ju
author_sort Choi, Bongkun
collection PubMed
description Calcific aortic valve disease (CAVD) accompanies inflammatory cell infiltration, fibrosis, and ultimately calcification of the valve leaflets. We previously demonstrated that dipeptidyl peptidase-4 (DPP-4) is responsible for the progression of aortic valvular calcification in CAVD animal models. As evogliptin, one of the DPP-4 inhibitors displays high specific accumulation in cardiac tissue, we here evaluated its therapeutic potency for attenuating valvular calcification in CAVD animal models. Evogliptin administration markedly reduced calcific deposition accompanied by a reduction in proinflammatory cytokine expression in endothelial nitric oxide synthase-deficient mice in vivo, and significantly ameliorated the mineralization of the primary human valvular interstitial cells (VICs), with a reduction in the mRNA expression of bone-associated and fibrosis-related genes in vitro. In addition, evogliptin ameliorated the rate of change in the transaortic peak velocity and mean pressure gradients in our rabbit model as assessed by echocardiography. Importantly, evogliptin administration in a rabbit model was found to suppress the effects of a high-cholesterol diet and of vitamin D2-driven fibrosis in association with a reduction in macrophage infiltration and calcific deposition in aortic valves. These results have indicated that evogliptin prohibits inflammatory cytokine expression, fibrosis, and calcification in a CAVD animal model, suggesting its potential as a selective therapeutic agent for the inhibition of valvular calcification during CAVD progression.
format Online
Article
Text
id pubmed-7824080
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78240802021-01-24 Evogliptin Suppresses Calcific Aortic Valve Disease by Attenuating Inflammation, Fibrosis, and Calcification Choi, Bongkun Kim, Eun-Young Kim, Ji-Eun Oh, Soyoon Park, Si-On Kim, Sang-Min Choi, Hyuksu Song, Jae-Kwan Chang, Eun-Ju Cells Article Calcific aortic valve disease (CAVD) accompanies inflammatory cell infiltration, fibrosis, and ultimately calcification of the valve leaflets. We previously demonstrated that dipeptidyl peptidase-4 (DPP-4) is responsible for the progression of aortic valvular calcification in CAVD animal models. As evogliptin, one of the DPP-4 inhibitors displays high specific accumulation in cardiac tissue, we here evaluated its therapeutic potency for attenuating valvular calcification in CAVD animal models. Evogliptin administration markedly reduced calcific deposition accompanied by a reduction in proinflammatory cytokine expression in endothelial nitric oxide synthase-deficient mice in vivo, and significantly ameliorated the mineralization of the primary human valvular interstitial cells (VICs), with a reduction in the mRNA expression of bone-associated and fibrosis-related genes in vitro. In addition, evogliptin ameliorated the rate of change in the transaortic peak velocity and mean pressure gradients in our rabbit model as assessed by echocardiography. Importantly, evogliptin administration in a rabbit model was found to suppress the effects of a high-cholesterol diet and of vitamin D2-driven fibrosis in association with a reduction in macrophage infiltration and calcific deposition in aortic valves. These results have indicated that evogliptin prohibits inflammatory cytokine expression, fibrosis, and calcification in a CAVD animal model, suggesting its potential as a selective therapeutic agent for the inhibition of valvular calcification during CAVD progression. MDPI 2021-01-01 /pmc/articles/PMC7824080/ /pubmed/33401457 http://dx.doi.org/10.3390/cells10010057 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Choi, Bongkun
Kim, Eun-Young
Kim, Ji-Eun
Oh, Soyoon
Park, Si-On
Kim, Sang-Min
Choi, Hyuksu
Song, Jae-Kwan
Chang, Eun-Ju
Evogliptin Suppresses Calcific Aortic Valve Disease by Attenuating Inflammation, Fibrosis, and Calcification
title Evogliptin Suppresses Calcific Aortic Valve Disease by Attenuating Inflammation, Fibrosis, and Calcification
title_full Evogliptin Suppresses Calcific Aortic Valve Disease by Attenuating Inflammation, Fibrosis, and Calcification
title_fullStr Evogliptin Suppresses Calcific Aortic Valve Disease by Attenuating Inflammation, Fibrosis, and Calcification
title_full_unstemmed Evogliptin Suppresses Calcific Aortic Valve Disease by Attenuating Inflammation, Fibrosis, and Calcification
title_short Evogliptin Suppresses Calcific Aortic Valve Disease by Attenuating Inflammation, Fibrosis, and Calcification
title_sort evogliptin suppresses calcific aortic valve disease by attenuating inflammation, fibrosis, and calcification
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824080/
https://www.ncbi.nlm.nih.gov/pubmed/33401457
http://dx.doi.org/10.3390/cells10010057
work_keys_str_mv AT choibongkun evogliptinsuppressescalcificaorticvalvediseasebyattenuatinginflammationfibrosisandcalcification
AT kimeunyoung evogliptinsuppressescalcificaorticvalvediseasebyattenuatinginflammationfibrosisandcalcification
AT kimjieun evogliptinsuppressescalcificaorticvalvediseasebyattenuatinginflammationfibrosisandcalcification
AT ohsoyoon evogliptinsuppressescalcificaorticvalvediseasebyattenuatinginflammationfibrosisandcalcification
AT parksion evogliptinsuppressescalcificaorticvalvediseasebyattenuatinginflammationfibrosisandcalcification
AT kimsangmin evogliptinsuppressescalcificaorticvalvediseasebyattenuatinginflammationfibrosisandcalcification
AT choihyuksu evogliptinsuppressescalcificaorticvalvediseasebyattenuatinginflammationfibrosisandcalcification
AT songjaekwan evogliptinsuppressescalcificaorticvalvediseasebyattenuatinginflammationfibrosisandcalcification
AT changeunju evogliptinsuppressescalcificaorticvalvediseasebyattenuatinginflammationfibrosisandcalcification